Physician profile
Fadi Samir Braiteh
NPI 1538268438
$2,732,002.42
in general payments reported to CMS, 2019-2025
75 companies · $300K in 2025
The $300K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $704K · 2020: $322K · 2021: $357K · 2022: $196K · 2023: $376K · 2024: $477K · 2025: $300K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $891K · Travel and Lodging: $131K · Consulting Fee: $97K · Food and Beverage: $26K · Honoraria: $7,850 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $890,657.69 |
| Travel and Lodging | $130,519.01 |
| Consulting Fee | $96,760.25 |
| Food and Beverage | $26,194.35 |
| Honoraria | $7,850.00 |
| Education | $335.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $339,809.57 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $236,097.63 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $229,480.82 | 2019-2025 | Opdivo, Augtyro, Reblozyl |
| Jazz Pharmaceuticals INC. | $209,591.64 | 2023-2025 | Zepzelca |
| Genentech USA, INC. | $184,569.09 | 2019-2025 | Alecensa, Tecentriq, Venclexta |
| Incyte Corporation | $166,363.79 | 2019-2025 | Pemazyre, Zynyz, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $127,451.75 | 2019-2024 | Fruzaqla |
| Taiho Oncology, INC. | $112,203.60 | 2019-2025 | |
| Celgene Corporation | $105,305.51 | 2019-2023 | Pomalyst, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $104,970.79 | 2019-2025 | Libtayo, Lynozyfic |
| Emd Serono, INC. | $86,502.40 | 2020-2025 | Tepmetko, Bavencio |
| Seagen INC. | $77,907.96 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Amgen INC. | $75,859.63 | 2019-2025 | Vectibix, Nplate, Lumakras |
| Stemline Therapeutics INC. | $66,207.32 | 2023-2024 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $60,971.55 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $47,697.49 | 2020-2025 | Vyloy, Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $38,856.92 | 2019-2025 | |
| Pfizer INC. | $37,190.26 | 2019-2025 | |
| Coherus Oncology, INC. | $36,139.72 | 2020-2024 | |
| Daiichi Sankyo INC. | $35,653.14 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Eisai INC. | $34,555.30 | 2019-2023 | |
| Beone Medicines USA, INC. | $30,931.61 | 2025 | Tevimbra, Brukinsa |
| Puma Biotechnology, INC. | $30,041.08 | 2019-2020 | |
| Exelixis INC. | $28,278.35 | 2019-2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $27,904.25 | 2020-2024 | Qinlock |
| Genzyme Corporation | $26,744.49 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $24,642.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $14,090.39 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,289.02 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $12,918.03 | 2021-2023 | Stimufend |
| Eusa Pharma (US) LLC | $10,762.28 | 2020-2021 | |
| Eli Lilly and Company | $10,194.03 | 2019-2023 | |
| Regeneron Pharmaceuticals, INC. | $10,156.17 | 2019 | |
| Astrazeneca Uk Limited | $9,101.25 | 2020-2023 | |
| Beigene USA, INC. | $8,863.35 | 2024-2025 | Tevimbra, Brukinsa |
| Novocure INC. | $8,615.48 | 2023-2024 | Optune Lua (Novottf-200t) |
| Kite Pharma, INC. | $7,430.00 | 2023 | Yescarta |
| Foundation Medicine, INC. | $5,682.01 | 2021 | |
| Gilead Sciences, INC. | $5,283.67 | 2021-2025 | Trodelvy |
| Abbvie INC. | $4,307.41 | 2023-2025 | Epkinly, Lupron Depot |
| Spectrum Pharmaceuticals INC. | $4,170.22 | 2019 | |
| F. Hoffmann-La Roche Ag | $4,150.62 | 2019-2021 | |
| G1 Therapeutics, INC. | $3,500.00 | 2021 | |
| Mirati Therapeutics, INC. | $2,927.49 | 2023-2024 | Krazati |
| Array Biopharma INC | $2,571.59 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Heron Therapeutics, INC. | $2,200.00 | 2021 | |
| Glaxosmithkline, LLC. | $2,195.45 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Janssen Scientific Affairs, LLC | $1,914.55 | 2024-2025 | Rybrevant |
| Janssen Biotech, INC. | $1,511.63 | 2019-2025 | Rybrevant, Talvey, Darzalex |
| Aadi Bioscience, INC. | $1,000.00 | 2023 | Fyarro |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $693.88 | 2020 | |
| Athenex Pharmaceutical Division, LLC | $521.72 | 2019 | |
| Boston Scientific Corporation | $510.24 | 2021-2023 | Icefx Cryoablation System, Infinion 16 |
| Karyopharm Therapeutics INC. | $388.66 | 2020-2025 | Xpovio |
| Sobi, INC | $339.58 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $262.76 | 2023-2025 | Orgovyx |
| Servier Pharmaceuticals LLC | $188.49 | 2023-2025 | Voranigo |
| Sirtex Medical INC | $164.19 | 2023-2025 | Sir-Spheres Microspheres |
| Morphosys, US INC. | $40.49 | 2023 | Monjuvi |
| Myriad Women'S Health, INC. | $23.02 | 2023 | Precisetumor |
| Caris Mpi, INC. | $22.51 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $22.14 | 2025 | Pyrukynd |
| Genmab U.S., INC. | $19.28 | 2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $18.95 | 2023 | Imbruvica |
| Janssen Pharmaceuticals, INC | $18.94 | 2023 | Xarelto |
| Clovis Oncology, INC. | $5.14 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$23,068.56 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Braiteh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.